2009
DOI: 10.1189/jlb.1008662
|View full text |Cite
|
Sign up to set email alerts
|

Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis

Abstract: Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10(-/-) mice with established chronic colitis, ethyl pyr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

10
131
1

Year Published

2010
2010
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 154 publications
(142 citation statements)
references
References 49 publications
10
131
1
Order By: Relevance
“…EP treatment of septic mice decreases circulating levels of HMGB1. Pretreatment with EP also prevents endotoxin lethality, inhibits the release of TNF and HMGB1 and ameliorates murine colitis and renal ischemia and reperfusion injury by decreasing HMGB1 release (19)(20)(21). Delayed treatment with EP also suppresses tumor growth significantly, although to a lesser extent.…”
Section: Introductionmentioning
confidence: 96%
“…EP treatment of septic mice decreases circulating levels of HMGB1. Pretreatment with EP also prevents endotoxin lethality, inhibits the release of TNF and HMGB1 and ameliorates murine colitis and renal ischemia and reperfusion injury by decreasing HMGB1 release (19)(20)(21). Delayed treatment with EP also suppresses tumor growth significantly, although to a lesser extent.…”
Section: Introductionmentioning
confidence: 96%
“…TNBS-induced colitis in BALB/c mice: BALB/c mice (n = 5-8/group) were used to evaluate the antiinflammatory effects of plecanatide on TNBS-induced colitis by previously described procedures [27,28] . Briefly, colitis was induced in 2-4 mo old female BALB/c mice by administering 2.5 mg TNBS in 50% ethanol into the lumen of the colon (injection volume 100 μL).…”
Section: Methodsmentioning
confidence: 99%
“…Colon tissues were removed and weighed. Distal sections were fixed, stained with H and E, and evaluated for histopathology and visual severity scores [27,28] . Scoring of the H and E-stained tissue sections employed the following criteria: Normalappearing crypts (score 0); abnormal crypt pathology without ulceration (score 1); depleted crypts with some ulceration/ inflammation (score 2); 20%-70% depleted crypts and increased ulceration/inflammation (score 3); > 70% depleted crypts with substantial ulceration/ inflammation (score 4); and totally ulcerated/inflamed colon with no crypts remaining (score 5).…”
Section: Tnbs-induced Colitis In Bdf-1 Micementioning
confidence: 99%
“…Pretreatment with EP can prevent endotoxin lethality and inhibit the release of TNF and HMGBI (12). It also ameliorates colitis and renal ischemia and reperfusion injury by decreasing HMGB I release (13,14). More importantly, treatment with EP significantly suppresses tumor growth, although to a slight extent, and decreases innate and adaptive immune cell infiltrates and serum IL-6 and HMGB 1 levels in the liver (15).…”
mentioning
confidence: 99%